HK1255877A1 - 含有抗人tslp受體抗體的藥物組合物 - Google Patents

含有抗人tslp受體抗體的藥物組合物

Info

Publication number
HK1255877A1
HK1255877A1 HK18114960.7A HK18114960A HK1255877A1 HK 1255877 A1 HK1255877 A1 HK 1255877A1 HK 18114960 A HK18114960 A HK 18114960A HK 1255877 A1 HK1255877 A1 HK 1255877A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
receptor antibody
human tslp
tslp receptor
human
Prior art date
Application number
HK18114960.7A
Other languages
English (en)
Inventor
Ikeda Megumi
Chikushi Akinori
Original Assignee
安斯泰來制藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 安斯泰來制藥株式會社 filed Critical 安斯泰來制藥株式會社
Publication of HK1255877A1 publication Critical patent/HK1255877A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
HK18114960.7A 2015-12-18 2018-11-22 含有抗人tslp受體抗體的藥物組合物 HK1255877A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015246826 2015-12-18
PCT/JP2016/087480 WO2017104778A1 (ja) 2015-12-18 2016-12-16 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物

Publications (1)

Publication Number Publication Date
HK1255877A1 true HK1255877A1 (zh) 2019-08-30

Family

ID=59056678

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114960.7A HK1255877A1 (zh) 2015-12-18 2018-11-22 含有抗人tslp受體抗體的藥物組合物

Country Status (12)

Country Link
US (3) US10994011B2 (zh)
EP (1) EP3391904A4 (zh)
JP (3) JP6897570B2 (zh)
KR (1) KR20180088906A (zh)
CN (1) CN108430507B (zh)
CA (1) CA3008779A1 (zh)
HK (1) HK1255877A1 (zh)
MX (1) MX2018007520A (zh)
PH (1) PH12018501243A1 (zh)
SG (2) SG11201805123XA (zh)
TW (1) TWI787161B (zh)
WO (1) WO2017104778A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865154A4 (en) * 2018-10-10 2022-11-09 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
BR112022016010A2 (pt) * 2020-02-13 2022-12-20 Amgen Inc Formulações de anticorpos anti-tslp humanos e métodos de tratamento de doenças inflamatórias
WO2022184074A1 (zh) * 2021-03-03 2022-09-09 正大天晴药业集团股份有限公司 含抗tslp抗体的药物组合物
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JP2004519205A (ja) 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
CA2555791A1 (en) * 2004-02-12 2005-08-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Highly concentrated liquid formulations of anti-egfr antibodies
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
CN101370831B (zh) 2006-01-13 2013-06-19 Irm责任有限公司 用于治疗过敏性疾病的针对胸腺基质淋巴细胞生成素受体的抗体
US7763070B2 (en) 2006-07-25 2010-07-27 C&C Vision International Limited “W” accommodating intraocular lens
AR067045A1 (es) 2007-06-20 2009-09-30 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP2011511638A (ja) 2008-02-07 2011-04-14 シェーリング コーポレイション 抗ｔｓｌｐｒ抗体の設計製作
SG10201900451SA (en) 2009-03-19 2019-02-27 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
WO2012015696A1 (en) 2010-07-26 2012-02-02 Baylor Research Institute Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
EP2968538A1 (en) 2013-03-15 2016-01-20 Bayer HealthCare LLC Anti-prolactin receptor antibody formulations
JP6380394B2 (ja) * 2013-08-09 2018-08-29 アステラス製薬株式会社 新規抗ヒトｔｓｌｐ受容体抗体

Also Published As

Publication number Publication date
RU2018126355A3 (zh) 2020-03-10
TWI787161B (zh) 2022-12-21
TW201733618A (zh) 2017-10-01
CN108430507B (zh) 2022-08-02
RU2018126355A (ru) 2020-01-22
EP3391904A4 (en) 2019-09-25
US20190111129A1 (en) 2019-04-18
JP2021127348A (ja) 2021-09-02
MX2018007520A (es) 2018-08-01
US20220023422A1 (en) 2022-01-27
JP6897570B2 (ja) 2021-06-30
JP2023029500A (ja) 2023-03-03
JPWO2017104778A1 (ja) 2018-10-04
PH12018501243A1 (en) 2019-01-28
SG10202012778YA (en) 2021-01-28
CA3008779A1 (en) 2017-06-22
EP3391904A1 (en) 2018-10-24
SG11201805123XA (en) 2018-07-30
JP7208302B2 (ja) 2023-01-18
KR20180088906A (ko) 2018-08-07
US20230398213A1 (en) 2023-12-14
US10994011B2 (en) 2021-05-04
US11712472B2 (en) 2023-08-01
CN108430507A (zh) 2018-08-21
WO2017104778A1 (ja) 2017-06-22
TW202310873A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
HK1257646A1 (zh) 包含雙特異性抗體建構物之醫藥組合物
IL254254A0 (en) chimeric antigen receptor
PL3294764T3 (pl) Kompozycje chimerycznego receptora antygenowego
HK1252009A1 (zh) 針對白細胞介素36受體(il-36r)的抗體
SG10201603721TA (en) Anti-CTLA-4 Antibodies
GB201503742D0 (en) Chimeric antigen receptor
IL256097A (en) Antibody epitope
GB201612317D0 (en) Antibody compositions
HK1250937A1 (zh) 穩定的包含cd147單克隆抗體的藥物製劑
HK1255877A1 (zh) 含有抗人tslp受體抗體的藥物組合物
HK1223123A1 (zh) 新穎抗人類 受體抗體
HK1250935A1 (zh) 穩定的包含cd147單克隆抗體的藥物製劑
IL267271A (en) Antibodies against il-5
GB201519900D0 (en) Chimeric antigen receptor
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201511196D0 (en) Monoclonal antibodies
AU2015903719A0 (en) Chimeric antigen receptor and uses thereof